It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese Patients
The hypothesis that non-erosive reflux disease (NERD) patients comprise various subgroups is gaining popularity. This study was conducted to investigate the possibility of categorizing NERD patients according to symptom types and response to acid-suppressive drug rabeprazole (RPZ) 10 mg/day. NERD patients were classified as grade N (endoscopically normal), M (minimal change), or erosive GERD, and answered a 51-item, yes-or-no questionnaire pre and post-treatment. Compared to erosive GERD, clear differences existed in pretreatment prevalence of symptoms and responsiveness to RPZ in grades N and M; the results suggested stomachaches (especially at night) were significant symptoms in grade N and dysmotility-like symptoms like bloated stomach were significant in grade M while gastroesophageal reflux symptoms were significant in erosive GERD. Clinical significance of classifying NERD was indicated from different symptoms and responsiveness to PPI.
KeywordsNERD Symptom Rabeprazole Minimal change Questionnaire
The study was supported by an unrestricted grant from Eisai Co., Ltd.
- 4.van Pixteren B, Numans ME, Bonis PA, Lau J (2006) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 19:CD002095Google Scholar
- 5.Tendler DA, Parker RA, Spechler SJ (1996) Heartburn: ethnic variations in prevalence and interpretation. Gastroenterology 110:A276Google Scholar
- 7.Bate CM, Green JR, Axon AT, Murray FE, Tildesley G, Emmas CE, Taylor MD (1997) Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 11:755–763PubMedCrossRefGoogle Scholar
- 8.Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML (1997) Omeprazole 10 milligrams once daily, Omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease-in general practice. Scand J Gastroenterol 32:765–773Google Scholar
- 10.Adachi K, Matsumori Y, Fujisawa T, Kamada T, Kusaka M, Ohumi T, Iwakiri R, Yamaguchi K, Danjo A, Hori K, Tomita T, Hayashi T, Haruma K, Fujimoto K, Miwa H, Kinoshita Y (2006) Symptom diversity of patients with reflux esophagitis: effect of omeprazole treatment. J Clin Biochem Nutr 39:46–54CrossRefGoogle Scholar
- 15.Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S (2002) Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Aliment Pharmacol Ther 97:1332–1339Google Scholar
- 17.Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H, Yagi J, Komazawa Y, Mihara T, Katsube T, Fujishiro H, Shizuku T, Hattori S, Yamamoto S, Kinoshita Y (2003) Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 18:1392–1398PubMedCrossRefGoogle Scholar
- 20.Fujiwara Y, Higuchi K, Shiba M, Yamamori K, Watanabe Y, Sasaki E, Tominaga K, Watanabe T, Oshitani N, Arakawa T (2005) Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol 100:754–758PubMedCrossRefGoogle Scholar
- 30.Shimoyama Y, Kusano M, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Moki F, Sugiyama T, Toki M, Ohwada T, Mori M (2005) Diagnosis of gastroesophageal reflux disease using a new questionnaire. J Gastroenterol Hepatol 20:643–647PubMedCrossRefGoogle Scholar